Sepsis

Sepsis is the body’s overwhelming and life-threatening response to infection that can lead to tissue damage, organ failure and death.1 In the United States, one person is diagnosed with sepsis every 20 seconds.1 In total, 1.6 million people diagnosed with sepsis each year.1

For in vitro diagnostics use only. 

Transform Your Laboratory

 

Sepsis is the leading cause of death in U.S. Hospitals with an in-hospital mortality rate of 16%1

 

Chance of Mortality from sepsis increases 8% for every hour that treatment is delayed1

 

Sepsis is the most expensive in-patient cost in U.S. hospitals (over $24 billion each year)1


Procalcitonin and Sepsis

Procalcitonin (PCT) helps determine if a patient has a bacterial infection (sepsis), the severity of the infection and whether the patient is responding to therapy.2 PCT is a more accurate diagnostic parameter for sepsis, a better predictor of mortality and a more reliable marker than other biomarkers, including C-reactive protein (CRP), Interleukins and Lactate levels.3

Sepsis PCT Molecule Image

ARCHITECT B.R.A.H.M.S. PCT4

  • Provides clinicians a risk assessment of critically ill patients on their first day of intensive care unit (ICU) admission for progression to severe sepsis and septic shock.
  • Aid in decision making on antibiotic discontinuation for patients with suspected or confirmed sepsis.
  • Excellent clinical sensitivity with a Limit of Quantitation (LoQ) of 0.01 ng/mL allowing for early indication, antibiotic stewardship and negative predictive values.
1. Sepsis Alliance Website, http://www.sepsis.org/resources/infographics, accessed September 2017.
2. Thermo Scientific B-R-A-H-M-S PCT Improving Infection Management.
3. Shiferaw, et al. The Role of Procalcitonin as a Biomarker in Sepsis. J Infect Dis Epidemiology. 2016; 2:006 Vol 2.
4. ARCHITECT B•R•A•H•M•S Package Inserts, G1-0601 R01, June 2017.
Magenta Background Image
 
Resources

Raising Awareness About Sepsis

Abbott is committed to increasing awareness about sepsis and has developed several educational resources to help clinicians and laboratorians learn more about sepsis.

Core Laboratory Menu
Intended Use and Important Safety Information

For In Vitro Diagnostic Use Only

 

CAUTION: United States Federal law restricts this device to sale and distribution by or on the order of a physician, or to a clinical laboratory. 

 

For complete assay information, see the assay specific package insert.

 

ARCHITECT B∙R∙A∙H∙M∙S PCT

Intended Use: The ARCHITECT B∙R∙A∙H∙M∙S PCT assay is a chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of procalcitonin (PCT) in human serum and plasma (lithium heparin and K2EDTA) on the ARCHITECT i System.

Used in conjunction with other laboratory findings and clinical assessments, the ARCHITECT B∙R∙A∙H∙M∙S PCT assay is intended for use as an:

Aid in the risk assessment of critically ill patients on their first day of intensive care unit (ICU) admission for progression to severe sepsis and septic shock.

 

Warning:  The ARCHITECT B∙R∙A∙H∙M∙S PCT assay is not indicated to be used as a stand-alone diagnostic assay and should be used in conjunction with clinical signs and symptoms of infection and other diagnostic evidence. 

 

Decisions regarding antibiotic therapy should NOT be based solely on PCT concentrations. PCT results should always be interpreted in the context of the clinical status of the patient and other laboratory results. Changes in PCT levels for the prediction of mortality, and overall mortality, are strongly dependent on many factors, including pre-existing patient risk factors and clinical course. The need to continue ICU care at Day 4 and other covariates (e.g., age and SOFA score) are also significant predictors of 28-day cumulative mortality risk. Certain patient characteristics, such as severity of renal failure or insufficiency, may influence PCT values and should be considered as potentially confounding clinical factors when interpreting PCT values. PCT levels may not be elevated in patients infected by certain atypical pathogens, such as Chlamydophila pneumoniae and Mycoplasma pneumoniae. 

 

Low PCT levels do not always indicate absence of bacterial infection. Falsely low PCT levels in the presence of bacterial infection may occur during the early course of infections, in localized infections, and in subacute infectious endocarditis.

 

Increased PCT levels may not always be related to systemic bacterial infection. The safety and performance of PCT-guided therapy for individuals younger than age 18 years, pregnant women, immunocompromised individuals or those on immunomodulatory agents, was not formally analyzed in the supportive clinical trials. ARCHITECT B∙R∙A∙H∙M∙S PCT results should not be used interchangeably with other methods for PCT determinations for monitoring patients.

 

 
 
 
 

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No

DO YOU WISH TO CONTINUE AND EXIT THE CORE LABORATORY WEBSITE?

Content is not under the control of corelaboratory.abbott.

Yes No